keyword
MENU ▼
Read by QxMD icon Read
search

interstitial lung disease guidelines

keyword
https://www.readbyqxmd.com/read/28149568/recommendations-for-the-management-of-idiopathic-pulmonary-fibrosis-in-south-africa-a-position-statement-of-the-south-african-thoracic-society
#1
REVIEW
Coenraad F N Koegelenberg, Gillian M Ainslie, Keertan Dheda, Brian W Allwood, Michelle L Wong, Umesh G Lalloo, Mohamed S Abdool-Gaffar, Hoosain Khalfey, Elvis M Irusen
Idiopathic pulmonary fibrosis (IPF) is a very specific form of a chronic, progressive fibroproliferative interstitial pneumonia of unknown aetiology. The disease is generally associated with a poor prognosis. Several international evidence-based guidelines on the diagnosis and management of IPF and other interstitial lung diseases (ILDs) have been published and updated in the last decade, and while the body of evidence for the use of some treatment modalities has grown, others have been shown to be futile and even harmful to patients...
December 2016: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28134084/pneumocystis-jiroveci-pneumonia-in-rheumatic-disease-a-20-year-single-centre-experience
#2
Christopher A Mecoli, Deanna Saylor, Allan C Gelber, Lisa Christopher-Stine
OBJECTIVES: Pneumocystis jiroveci pneumonia (PJP) is an opportunistic infection with high mortality among patients with underlying rheumatologic conditions. Given the paucity of prospective data to guide treatment, clinical guidelines to initiate PJP prophylaxis are based on expert opinion and identify patients on ≥20 mg daily prednisone for ≥4 weeks duration for treatment. Herein we describe the PJP experience in rheumatic disease over a 20-year period at a single academic medical centre to investigate this 20 mg threshold and risk associated with lymphocyte counts, co-existing lung disease and immunosuppressive medications...
January 27, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28118995/idiopathic-pulmonary-fibrosis-current-and-future-directions
#3
E Soo, H Adamali, A J Edey
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pneumonia and is increasingly recognised. Prior to the advent of effective therapies, achieving an early diagnosis was arguably of little prognostic consequence given IPF was considered an untreatable and uniformly fatal disease. The advent of new drug treatments has given hope for the future and raised the profile of IPF. International management guidelines highlight the critical role of radiology as part of an interstitial lung disease multidisciplinary team approach in reaching an accurate and early diagnosis of IPF...
January 21, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/28099038/an-exome-sequencing-study-to-assess-the-role-of-rare-genetic-variation-in-pulmonary-fibrosis
#4
Slavé Petrovski, Jamie L Todd, Michael T Durheim, Quanli Wang, Jason W Chien, Fran L Kelly, Courtney Frankel, Caroline M Mebane, Zhong Ren, Joshua Bridgers, Thomas J Urban, Colin D Malone, Ashley Finlen Copeland, Christie Brinkley, Andrew S Allen, Thomas O'Riordan, John G McHutchison, Scott M Palmer, David B Goldstein
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is an increasingly recognized, often fatal lung disease of unknown etiology. OBJECTIVES: The aim of this study was to use whole-exome sequencing to improve our understanding of the genetic architecture of pulmonary fibrosis. METHODS: We performed a case-control exome-wide collapsing analysis including 262 unrelated individuals with pulmonary fibrosis; clinically classified as IPF according to ATS/ERS/JRS/ALAT guidelines (81...
January 18, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28088797/automated-interpretation-of-pulmonary-function-tests-in-adults-with-respiratory-complaints
#5
Marko Topalovic, Stefan Laval, Jean-Marie Aerts, Thierry Troosters, Marc Decramer, Wim Janssens
BACKGROUND: The use of pulmonary function tests is primarily based on expert opinion and international guidelines. Current interpretation strategies are using predefined cutoffs for the description of a typical pattern. OBJECTIVES: We aimed to explore the predicted disease outcome based on the American Thoracic Society/European Respiratory Society (ATS/ERS) interpreting strategy. Subsequently, we investigated whether an unbiased machine learning framework integrating lung function with clinical variables may provide alternative decision trees resulting in a more accurate diagnosis...
2017: Respiration; International Review of Thoracic Diseases
https://www.readbyqxmd.com/read/28088339/evidence-based-management-of-systemic-sclerosis-navigating-recommendations-and-guidelines
#6
REVIEW
Russell Edward Pellar, Janet Elizabeth Pope
OBJECTIVES: Systemic sclerosis (SSc) is a rare heterogeneous connective tissue disease. Recommendations addressing the major issues in the management of SSc including screening and treatment of organ complications are needed. METHODS: The updated European League Against Rheumatism/European Scleroderma Trial and Research (EULAR/EUSTAR) and the British Society of Rheumatology (BSR) and British Health Professionals in Rheumatology (BHPR) guidelines were compared and contrasted...
December 9, 2016: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/27932290/the-diagnosis-of-idiopathic-pulmonary-fibrosis-current-and-future-approaches
#7
REVIEW
Fernando J Martinez, Alison Chisholm, Harold R Collard, Kevin R Flaherty, Jeffrey Myers, Ganesh Raghu, Simon L F Walsh, Eric S White, Luca Richeldi
With the recent development of two effective treatments for patients with idiopathic pulmonary fibrosis, an accurate diagnosis is crucial. The traditional approach to diagnosis emphasises the importance of thorough clinical and laboratory evaluations to exclude secondary causes of disease. High-resolution CT is a critical initial diagnostic test and acts as a tool to identify patients who should undergo surgical lung biopsy to secure a definitive histological diagnosis of usual interstitial pneumonia pattern...
January 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27919708/early-interstitial-lung-disease-in-microscopic-polyangiitis-case-report-and-literature-review
#8
Marcos García-Nava, Heidegger Mateos-Toledo, Ana Patricia Georgina Guevara-Canseco, Cesar Eduardo Infante-González, Diego Alberto Reyes-Nava, Emilio Estrada-Castro
Microscopic polyangiitis (MPA) is a systemic disease included in the Chapel Hill 2012 Classification as necrotizing vasculitis affecting capillaries, venules and arterioles. It usually expresses antineutrophil cytoplasmic antibodies (ANCA) and has a perinuclear immunofluorescence pattern and correlation with anti-myeloperoxidase (MPO) antibodies. Capillaritis with alveolar hemorrhage is the most common manifestation of lung disease. Interstitial lung disease (ILD) is uncommon, with usual interstitial pneumonia being the predominant pattern...
December 2, 2016: Reumatología Clinica
https://www.readbyqxmd.com/read/27729263/utility-of-transbronchial-versus-surgical-lung-biopsy-in-the-diagnosis-of-suspected-fibrotic-interstitial-lung-disease
#9
Jamie S Sheth, John A Belperio, Michael C Fishbein, Ella A Kazerooni, Amir Lagstein, Susan Murray, Jeff L Myers, Richard H Simon, Thomas H Sisson, Baskaran Sundaram, Eric S White, Meng Xia, David Zisman, Kevin R Flaherty
BACKGROUND: Surgical lung biopsy (SLB) is invasive and not possible in all patients with undiagnosed interstitial lung diseases (ILD). We hypothesized that transbronchial biopsy (TBB) findings combined with clinical and high resolution computed tomography (HRCT) data leads to a confident diagnosis congruent to SLB, and therefore avoids the need for SLB in some patients. METHODS: We evaluated 33 patients being evaluated for suspected ILD who underwent HRCT, TBB and SLB...
October 8, 2016: Chest
https://www.readbyqxmd.com/read/27679963/pulmonary-hypertension-associated-with-chronic-lung-diseases
#10
Manuela Funke, Thomas Geiser, Otto D Schoch
In 2015, the international guidelines for diagnosis and treatment of pulmonary hypertension (PH) were updated. Group 3 of the current classification includes PH associated with chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), other pulmonary diseases with restrictive and obstructive pattern, sleep-disordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude, and developmental lung diseases [1]. PH associated with COPD and ILD is common but difficult to manage, as no long-term randomised controlled trial (RCT) has been conducted with specific pulmonary arterial hypertension (PAH) drugs in PH associated with COPD, and the one recent RCT in PH associated with ILD had to be stopped early due to a possible increased risk of death and side effects in the treatment group...
2016: Swiss Medical Weekly
https://www.readbyqxmd.com/read/27660509/surgical-lung-biopsy-for-the-diagnosis-of-interstitial-lung-disease-in-england-1997-2008
#11
John P Hutchinson, Tricia M McKeever, Andrew W Fogarty, Vidya Navaratnam, Richard B Hubbard
International guidelines and new targeted therapies for idiopathic pulmonary fibrosis have increased the need for accurate diagnosis of interstitial lung disease (ILD), which may lead to more surgical lung biopsies. This study aimed to assess the risk of this procedure in patients from the UK.We used Hospital Episodes Statistics data from 1997 to 2008 to assess the frequency of surgical lung biopsy for ILD in England, UK. We identified cardiothoracic surgical patients using International Classification of Diseases revision 10 codes for ILD and Office of Population Censuses and Surveys Classification of Interventions and Procedures version 4 codes for surgical lung biopsy...
November 2016: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/27654717/a-national-guideline-and-ild-pak-registry-report-recent-landmarks-in-the-understanding-of-interstitial-lung-diseases-in-pakistan
#12
Mosavir Ansarie
No abstract text is available yet for this article.
September 2016: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/27215507/efficacy-of-adalimumab-in-sarcoidosis-patients-who-developed-intolerance-to-infliximab
#13
Heleen A Crommelin, Leone M van der Burg, Adriane D M Vorselaars, Marjolein Drent, Coline H M van Moorsel, Ger T Rijkers, Vera H M Deneer, Jan C Grutters
BACKGROUND: Tumor necrosis factor-alpha (TNF-α) inhibitors are regarded as the third-line therapy in sarcoidosis, the first choice generally being infliximab. To date, data regarding response to adalimumab in sarcoidosis patients intolerant to infliximab are lacking. The objective of this retrospective observational study was to establish if adalimumab could achieve stabilization or improvement of the disease in refractory sarcoidosis patients who developed intolerance to infliximab...
June 2016: Respiratory Medicine
https://www.readbyqxmd.com/read/27185993/bronchoalveolar-lavage-cellular-analyses-in-conjunction-with-high-resolution-computed-tomography-imaging-as-a-diagnostic-intervention-for-patients-with-suspected-interstitial-lung-disease
#14
Ammaiyappan Chockalingam, Ranganathan Duraiswamy, Madhavan Jagadeesan
BACKGROUND: Bronchoalveolar lavage (BAL) has gained acceptance for diagnosis of Interstitial lung disease (ILD). The advent of high-resolution computed tomography (HRCT) has reduced the clinical utility of BAL. This work has utilized the recommendations of the American Thoracic Society (ATS) to optimize BAL and the findings have been associated with clinical examination and HRCT to precisely narrow down the cause of ILD. MATERIALS AND METHODS: BAL was performed on ILD suspects at the target site chosen based on HRCT...
May 2016: Lung India: Official Organ of Indian Chest Society
https://www.readbyqxmd.com/read/27180021/multicentre-evaluation-of-multidisciplinary-team-meeting-agreement-on-diagnosis-in-diffuse-parenchymal-lung-disease-a-case-cohort-study
#15
Simon L F Walsh, Athol U Wells, Sujal R Desai, Venerino Poletti, Sara Piciucchi, Alessandra Dubini, Hilario Nunes, Dominique Valeyre, Pierre Y Brillet, Marianne Kambouchner, António Morais, José M Pereira, Conceição Souto Moura, Jan C Grutters, Daniel A van den Heuvel, Hendrik W van Es, Matthijs F van Oosterhout, Cornelis A Seldenrijk, Elisabeth Bendstrup, Finn Rasmussen, Line B Madsen, Bibek Gooptu, Sabine Pomplun, Hiroyuki Taniguchi, Junya Fukuoka, Takeshi Johkoh, Andrew G Nicholson, Charlie Sayer, Lilian Edmunds, Joseph Jacob, Maria A Kokosi, Jeffrey L Myers, Kevin R Flaherty, David M Hansell
BACKGROUND: Diffuse parenchymal lung disease represents a diverse and challenging group of pulmonary disorders. A consistent diagnostic approach to diffuse parenchymal lung disease is crucial if clinical trial data are to be applied to individual patients. We aimed to evaluate inter-multidisciplinary team agreement for the diagnosis of diffuse parenchymal lung disease. METHODS: We did a multicentre evaluation of clinical data of patients who presented to the interstitial lung disease unit of the Royal Brompton and Harefield NHS Foundation Trust (London, UK; host institution) and required multidisciplinary team meeting (MDTM) characterisation between March 1, 2010, and Aug 31, 2010...
July 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27102182/management-of-myositis-related-interstitial-lung-disease
#16
REVIEW
Julie Morisset, Cheilonda Johnson, Eric Rich, Harold R Collard, Joyce S Lee
Interstitial lung disease (ILD) is a frequent pulmonary manifestation and an important cause of morbidity and mortality in patients with idiopathic inflammatory myopathy. Myositis-related ILD presents a therapeutic challenge for clinicians, as there are no available guidelines to help with management decisions. This review covers the existing evidence on the pharmacologic and nonpharmacologic management of myositis-related ILD, highlighting the lack of randomized controlled data to guide treatment. Given the absence of existing guidelines to inform treatment decisions, we provide a comprehensive summary, including dosing, side effects, and suggested monitoring of the commonly used immunosuppressive agents and a proposed treatment algorithm based on the existing literature...
November 2016: Chest
https://www.readbyqxmd.com/read/27098533/sabr-vs-limited-resection-for-non-small-cell-lung-cancer-are-we-closer-to-an-answer
#17
REVIEW
Hanbo Chen, Alexander V Louie
Lobectomy is currently the guideline-recognized gold standard for the treatment of early-stage non-small cell lung cancer (ES-NSCLC) in patients who are surgical candidates. In patients who are not medically fit for surgery, stereotactic ablative radiotherapy (SABR) is the treatment of choice with good reported rates of local control and overall survival. For patients at high risk for lobectomy, sublobar resection (SLR) may achieve similar outcomes as lobectomy, especially for peripheral tumors ≤2 cm. While there are merits to both SLR and SABR for these high-risk patients, evidence is conflicting on which may be preferred in the context of clinical and cost-effectiveness outcomes...
June 2016: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/27048142/-federal-clinical-practice-guidelines-for-the-diagnosis-prevention-and-treatment-of-pneumoconiosis
#18
L V Artemoval, N V Baskova, T B Burmistrova, E A Buryakinal, I V Buhtiyarov, A Yu Bushmanov, O S Vasilyeva, V G Vlasov, Y Y Gorblyansky, S A Zhabina, O N Zaharinskaya, N F Ismerov, E V Kovalevsky, G V Kuznetsova, L P Kuzmina, T A Kunyaeva, I I Logvinenko, L A Lutsenko, N N Mazitova, T Yu Obukhova, O V Odintseva, G P Orlova, L A Panacheva, I N Piktushanskaya, A E Plyukhin, E L Poteryaeva, S M Pravilo, V V Razumov, N A Roslaya, O F Roslyi, O P Rushkevich, V A Semenihin, P V Serebryakov, E L Smirnova, N S Sorkina, E S Tsidil'kovskaya, E V Chasovskikh, L A Shpagina
The purpose of development of this clinical practice guidelines was to provide evidence-based protocols that help the practitioner and the patient make the right decision for the health assessment, treatment and prevention of pneumoconiosis. Pneumoconiosis is the interstitial lung disease of occupational origin caused by prolonged inhalation of inorganic dust, characterized by chronic diffuse aseptic inflammation in lung tissue with the development of pulmonary fibrosis. Currently, thereare no treatment that provide a cure pulmonary fibrosis and changes in the dynamics of decline in lung function...
2016: Meditsina Truda i Promyshlennaia Ekologiia
https://www.readbyqxmd.com/read/27027811/management-of-connective-tissue-diseases-associated-interstitial-lung-disease-a-review-of-the-published-literature
#19
REVIEW
Beth Wallace, Dharshan Vummidi, Dinesh Khanna
PURPOSE OF REVIEW: Interstitial lung disease (ILD), though a common and often a severe manifestation of many connective tissue diseases (CTD), is challenging to manage because of its variable presentation and the relative lack of guidelines to assist the clinician. In this review, we discuss the approach to diagnosis, treatment, and monitoring patients with CTD-associated ILD, with a focus on systemic sclerosis (SSc), rheumatoid arthritis (RA), and idiopathic inflammatory myopathy (IIM)...
May 2016: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/27023695/patterns-and-economic-burden-of-hospitalizations-and-exacerbations-among-patients-diagnosed-with-idiopathic-pulmonary-fibrosis
#20
Yanni F Yu, Ning Wu, Chien-Chia Chuang, Rosa Wang, Xiaoyun Pan, Nicole N Benjamin, Giovanna Devercelli, David B Coultas
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a rare and fatal restrictive respiratory disease under the idiopathic lung disease (ILD) class. IPF is a form of chronic, progressive fibrosing interstitial pneumonia and has more scarring, less inflammation, and poorer prognosis than most other ILD forms. Exacerbation of IPF is rapid, with unpredictable deterioration of lung function, and is associated with short-term mortality. The American Thoracic Society (ATS) evidence-based guidelines for diagnosis and management of IPF reports that the incidence of acute exacerbations is between 5%-10%...
April 2016: Journal of Managed Care & Specialty Pharmacy
keyword
keyword
120816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"